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Methods: Using an in-house designed prototype enzyme-linked immunosorbent assay (ELISA) tar-
geting neurogranin C-terminally, we studied neurogranin in paired CSF/plasma samples of controls
(n 5 29) versus patients experiencing MCI, or dementia, due to AD (in total n 5 59).
Results: CSF neurogranin was increased in AD and positively correlated with CSF tau, whereas
there was a negative relationship between CSF neurogranin (and tau) and CSFAb1–42/Ab1–40. No dif-
ferences were detected in plasma neurogranin between controls and AD. Also, there was no correla-
tion between CSF and plasma neurogranin, excluding confounding effects of the latter.
Discussion: This study strengthens the potential of neurogranin as an AD CSF biomarker, which
now needs validation in larger studies. As tools, straightforward immunoassays can be used, as
demonstrated by the described ELISA.
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There is a need for improved early diagnosis of Alz-
heimer’s disease (AD), especially in stages before dementia
onset. Current parameters, such as the cerebrospinal fluid
(CSF) biomarkers tau and Ab1–42, are highly predictive for
the imminent occurrence of AD but have poor prognostic
value regarding onset of cognitive decline [1]. From a neuro-
pathologic perspective, the link between cognitive decline
and tau/tangle or amyloid/plaque pathology seems complex
[2]. Because the loss of brain synapses is much closer related
to cognitive decline [3,4], a synaptic CSF biomarker could
thus improve the prognostic accuracy of the AD biomarker
panel.
Gained insights on neurogranin suggest that this postsyn-
aptic protein could be a surrogate biomarker for synaptic loss.
Neurogranin is important for long-term potentiation and
learning abilities, mostly through interaction with calmodulin
[5], and is found in CSF under physiological conditions [6–8].
Interestingly, in AD, neurogranin levels are decreased in
the brain [9,10], whereas CSF levels are elevated as
shown in our pilot study using immunoprecipitation and
semiquantitative immunoblotting [11]. Recently, the AD-
related increase in CSF neurogranin levels, which were more-
over correlated with CSF tau concentrations, was verified by
an enzyme-linked immunosorbent assay (ELISA) based on a
new monoclonal antibody (mAb). Furthermore, the elevated
neurogranin levels correlated with cognitive decline in
prodromal AD [12]. These findings clearly support the
potential of neurogranin as an AD CSF biomarker and war-
rants further studies. Finally, there is emerging evidence
that neurogranin is also circulating in blood in the ng/mL
range [13,14]. However, whether neurogranin could also be
considered as an AD plasma biomarker has not been
investigated up to date.
Accordingly, straightforward, yet highly specific, robust
tools are required for further studies, allowing accurate mea-
surements of neurogranin. In detail, hybrid immunoaffinity-
mass spectrometry revealed CSF neurogranin as a pool of
predominantly C-terminal peptides, whereas the full-length
sequence was only present in minor quantities [12]. Targeting
specific metabolic fragments is suggested to improve diag-
nostic performance of immunoassays, as demonstrated for
tau of which predominantly N-terminal andmid-domain frag-
ments are distinguished in CSF [15]. Therefore, we aimed to
develop an ELISA during this study specific for the C-termi-
nal part of neurogranin. Additionally, using this new proto-
type assay, we assessed neurogranin as a biomarker in CSF
and plasma during an explorative study in paired CSF/plasma
samples, collected from participants covering the whole dis-
ease spectrum of AD, from cognitively normal to experi-
encing full-blown dementia. The relationship between
neurogranin and available clinical parameters, e.g. Mini-
Mental State Examination (MMSE), was considered during
the analysis as well as the link with the classical AD CSF bio-
markers, e.g. CSF tau, but also plasma tau. Recent workdemonstrated no correlation between tau levels in CSF and
plasma [16]. By selecting a subgroup of patients with very
high CSF tau levels, we wanted to confirm this observation
and extend it by also investigating the relationship between
neurogranin and tau in CSF/plasma. Finally, because the ratio
CSF Ab1–42/CSF Ab1–40 appears to perform diagnostically
better than the levels of the single analyte CSF Ab1–42 [17],
we investigated the relationship between CSF neurogranin
and CSF Ab1–42/CSF Ab1–40.2. Methods
2.1. Study population
CSF/plasma samples from patients recruited in the Mem-
ory Clinic and Department of Neurology of Hospital
Network Antwerp were selected from the Biobank of Insti-
tute Born-Bunge (Antwerp, Belgium). Patients with MCI
due to AD (referred to as “MCI” hereafter) (n5 20), demen-
tia due to AD (“AD”) (n5 20), and patients with MCI or AD
with high CSF T-tau levels (“high tau”) (n 5 20) were
included. Diagnosis was based on the National Institute on
Aging-Alzheimer’s Association criteria [18,19], whereby
CSF biomarkers Ab1–42, T-tau, and P-tau181P were
analyzed at the Institute Born-Bunge using commercial kits
(INNOTEST b-AMYLOID(1–42), INNOTEST hTAU-Ag,
and INNOTEST PHOSPHO-TAU(181P); Fujirebio Europe;
Belgium) and whereby the institute’s cutoff values were
applied to discriminate AD from controls [20]. All patients
had high probability of AD etiology except for one MCI pa-
tient who had intermediate probability. Also, one MCI pa-
tient carried a PSEN1 mutation. The “high tau” group
included MCI (n 5 2) and AD (n 5 18) patients demon-
strating CSF T-tau levels .1200 pg/mL. Regarding the par-
ticipants of the control group (“CTRL”) (n 5 30),
cognitive deterioration was ruled out by neuropsychological
screening, as well as neurologic or psychiatric antecedents,
or central nervous system disorders. The study was approved
by the local ethics committee (University of Antwerp). All
subjects gave written informed consent.
CSF samples were obtained by lumbar puncture (LP) at
the L3/L4 or L4/L5 interspace, collected in polypropylene
tubes, and immediately frozen in liquid nitrogen. Plasma
samples were collected immediately after LP, centrifuged
at room temperature (RT) (10 min, 3000 rpm), transferred
to polypropylene tubes, and immediately frozen in liquid ni-
trogen. Both types of samples were stored at 280C until
analysis.
From one-third of the participants, brain magnetic reso-
nance imaging scans were available. The hippocampal vol-
ume (HCV) was visually rated by two radiologists,
separately, blinded for diagnosis [21]. If needed, a consensus
rate on divergent rates was discussed. On some participants
APOE genotyping was performed. The single nucleotide
polymorphisms in APOE—rs429358 and rs7412—deter-
mining the ε2/ε3/ε4 polymorphism were genotyped by
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2.2. Neurogranin ELISA for CSF and plasma
Ninety-six well microtiter plates were coated with mAb
Ng7 in phosphate-buffered saline (PBS), for 1 h at RT. After
washing with PBS containing 0.05% Tween-20 (PBST), the
plates were blocked with blocking reagent (PBS; 0.5%
casein; 0.05% ProClin; 2 h at RT). The calibrator, synthetic
full-length neurogranin (custom-made by ProteoGenix,
France) was prepared in sample diluent (SD; PBS; 0.1%
casein; 0.4% Triton; 0.05% ProClin) at an initial concentra-
tion of 2000 pg/mL and subsequent fourfold dilutions were
made. Samples (CSF undiluted; plasma 1:16 in SD) and cali-
brator dilutions were simultaneously incubated overnight at
RT with the polyclonal antibody (pAb) 07-425 (cat nr 07-
425; Merck Millipore, USA) in SD. After washing, horse-
radish peroxidase (HRP)–conjugated donkey anti-rabbit
Ab (diluted 1:2.500 in conjugate diluent, PBS; 0.1% casein;
0.05% ProClin) was added. After incubation for 1 h at RT,
the plates were washed and 3,30,5,50-Tetramethylbenzidine
solution was added to engage development. After 30 min
at RT, the colouring reaction was stopped with 1 M sulfuric
acid and plates were read spectrophotometrically in a
BioTek microplate reader, at 450 nm (630 nm as reference
wavelength). Neurogranin levels were calculated via inter-
polation (log/log; 4PL weighted 1/Y2) based on the cali-
brator curve.
2.3. Tau ELISA for plasma
Ninety-six well microtiter plates were coated overnight
with mAb 77E9 (cat nr MMS-5018; Covance, USA) in
PBS, at 2C–8C. After washing with PBST, the plates
were blocked with blocking reagent for 2 h at RT. As cali-
brator, Escherichia coli recombinant tau441 (cat nr T-
1001-1; rPeptide, USA) was prepared in sample buffer
(SB; PBS; 0.1% casein; 0.4% Triton; 0.05% ProClin; blue
coloring reagent) at an initial concentration of 1200 pg/mL
and subsequent threefold dilutions were made. Undiluted
plasma samples and calibrator dilutions were simulta-
neously incubated with biotinylated mAb ADx215 in SB
(3 h, RT). After washing, polyHRP–conjugated streptavidin
(SDT; Germany) diluted 1:2.500 in SD was added and incu-
bation of 30 min at RT followed. Plates werewashed, and the
same development protocol was followed as for neurogra-
nin. Tau levels were calculated via interpolation (log/log;
4PL weighted 1/Y2) based on the calibrator curve. However,
because this research assay is not yet fully developed, the
quantifications are expressed as arbitrary units (AU).
2.4. ELISA for the CSF biomarkers total-tau, Ab1–42, and
Ab1–40
Based on recent work [15], we chose to measure CSF tau
with the total-tau kit by EUROIMMUN (Germany). Thisassay measures the N-terminal part of CSF tau, in contrast
to the INNOTEST hTAU-Ag assay targeting fragments
from the proline-rich region. Additionally, the total-tau kit
enables quantification of tau levels above 1200 pg/mL, con-
trary to the INNOTEST, because it sets the highest calibrator
at 1462 pg/mL. This enabled us to also accurately quantify
CSF tau in the “high tau” group.
For the quantification of CSFAb1–42 and CSFAb1–40, we
used the b-Amyloid (1–42) ELISA and b-Amyloid (1–40)
ELISA by EUROIMMUN. The former assay has been opti-
mized to ensure reproducible clinical results, in contrast to
INNOTEST b-AMYLOID(1–42) [22]. All three European
Conformity (CE)-certified assays by EUROIMMUN (CSF
total-tau, CSFAb1–42, and CSFAb1–40) were performed ac-
cording to the kit-insert, using the lyophilized, ready-to-use
calibrators and standardized protocols.
2.5. Statistical analysis
Statistical analyses were performed using SPSS 20.0
for IBM, and R version 3.1.2. Based on a Shapiro-Wilk
test, all data were skewed, so nonparametric tests were
used. A Kruskal-Wallis test was performed to com-
pare data between all groups. To compare gender distribu-
tion, a c2 test was used. Mann-Whitney U tests were
performed to compare two groups separately. For correla-
tions, we applied Spearman’s r correlation analysis.
Additional statistical analyses (covariate, linear mixed
model) are described in Supplementary Figs. and Tables.
Results were considered significant for P values ,.05.
Figures were made using GraphPad Prism 6.02 and R
version 3.1.2.
3. Results
3.1. Analytical characteristics of the neurogranin assay
The research prototype neurogranin ELISA described in
this study involved two Abs targeting the C-terminal part of
neurogranin: a capture mouse mAb, i.e. Ng7, and a detector
rabbit pAb, defined as “07-425” throughout this article. The
generation of Ng7 is described elsewhere [12], whereas 07-
425 is commercially available by Merck Millipore. To
verify the C-terminal epitope of both Abs, epitope-
mapping was performed with eight biotinylated synthetic
peptides (14-mers), covering the sequence R51-D78 and
overlapping each other with 12 amino acids. The epitope
of Ng7 was confirmed as targeting aa53(R)-64(A) of neuro-
granin (Fig. 1). The epitope of 07-425 encompasses
aa66(V)-78(D), downstream from the Ng7 epitope, allow-
ing both Abs to be combined in a two-site ELISA format.
To evaluate the sensitivity of this set-up, three CSF samples
with low endogenous neurogranin levels were run in 10
replicates and the lowest concentration that could be
quantified, based on the standard curve (in duplicate),
with a coefficient of variation of 20% was 3 pg/mL. The
standard curve consisted of fourfold serially dilutions
Fig. 1. Epitope mapping of Ng7 and 07-425. Epitope mapping was performed with overlapping synthetic peptides, of mAb Ng7, generated in mice immunized
with a synthetic neurogranin peptide, aa G52-P75, and the polyclonal anti-neurogranin antibody, 07-425. Based on this analysis, the minimal epitope of Ng7 is
R53-A64 (open box) and the specificity of 07-425 for V66-D78 (gray box) is confirmed.
A. De Vos et al. / Alzheimer’s & Dementia 11 (2015) 1461-14691464(2000–0.12 pg/mL) of synthetic full-length neurogranin
(aa1-78), as calibrator. Eventually, the range of the resulting
immunoassay, i.e. 3–2000 pg/mL, covered 86% of undi-
luted CSF samples and 76% of 16-fold diluted plasma sam-
ples during the study.
Because both Ng7 and 07-425 target the collagen-like
region of neurogranin (homology scoring between collagen
and this domain ranges from 39 to 55% [aa identity]) and
because collagen is an abundant protein in the human brain
and vascular system [23–25], cross-reactivity was ad-
dressed of both Abs on a few human collagen types, i.e.
type I, III, and IV. Ng7 did not display any cross-
reactivity in Western blotting or one-site as well as two-
site ELISA nor did 07-425 (Supplementary Figs. 1 and 2,
Supplementary Table 1).Table 1
Summary of the demographic, clinical, and biomarker data of the population
Demographic, clinical, and biomarker data CTRL MCI
n (F/M) 29 (18/11) 20 (13/7)
Age (y) 48 (42–62) 78 (73–82
MMSE at LP (/30) NA 25 (22–26
MMSE change per year (U/y) NA 21.03 (22.47
Disease duration (y) NA 4 (2–6)
CSF neurogranin (pg/mL) 7.8 (1.5–22.8) 33.8 (19.0–7
CSF total-tau (pg/mL) 215 (134–295) 434 (331–5
CSF Ab1–42 (pg/mL) 341 (205–461) 192 (151–2
CSF Ab1–40 (pg/mL) 4531 (3216–5703) 5093 (4290–
Ratio CSF Ab1–42/CSF Ab1–40 0.071 (0.065–0.087) 0.037 (0.031–
Plasma neurogranin (ng/mL) 1.29 (0.15–3.78) 0.14 (0.05–1
Plasma tau (AU) 11.7 (5.7–26.7) 16.7 (10.3–2
Abbreviations: CTRL, controls; MCI, mild cognitive impairment; AD, Alzheime
not applicable; LP, lumbar puncture; CSF, cerebrospinal fluid; Ab1–40, amyloid b
immunosorbent assay.
NOTE. CSF samples were analyzed using the research prototype ELISA for neu
total-tau, b-Amyloid (1–42) ELISA for CSF-Ab1–42, and b-Amyloid (1–40) ELISA
using the same ELISA for neurogranin on the one hand and a research prototype ta
data are median values with 25th and 75th quartiles, except for n. For details on s
NOTE. *P, .001 versus CTRL, yP, .05 versus MCI, zP, .001 versus MCI/AD
CTRL.3.2. Levels of CSF neurogranin in different diagnostic
groups
Four assays were run on the CSF samples, blinded from
clinical diagnosis: the research ELISA to measure neurogra-
nin as well as three commercial ELISAs (EUROIMMUN)
for CSF total-tau, CSF Ab1–42, and CSF Ab1–40. Subse-
quently, one sample from the CTRL group, demonstrating
extremely low CSF Ab1–40 (22 pg/mL), was excluded.
Also, one sample from the high tau group was omitted
because the high CSF T-tau levels, based on the INNOTEST
hTAU-Ag test, could not be confirmed (133 pg/mL). It should
be pointed out that in case CSF neurogranin levels were
below the assay’s lower limit of quantification (LLOQ),
i.e. 3 pg/mL, values were equaled to LLOQ/2. Table 1AD High tau P value
20 (11/9) 19 (13/6) .019
)* 77 (71–84)* 77 (70–82)* ,.001
) 19 (15–23)y 18 (16–24)y .026
to 20.51) 21.46 (23.34 to 20.30) 22.07 (25.64 to 21.28) .466
2 (1–4) 2 (1–3) .128
3.3)*,z 36.6 (22.4–51.9)*,z 102.3 (68.9–149.4)* ,.001
80)*,z 506 (423–585)*,z 813 (703–1041)* ,.001
54)x 170 (139–235)* 200 (141–228)x ,.001
6999) 4917 (4143–5460) 6039 (5104–8380)x,{ .016
0.044)* 0.037 (0.031–0.047)* 0.028 (0.025–0.036)*,{,y ,.001
.01)# 0.88 (0.03–2.91) 0.11 (0.02–1.91) .138
6.2) 16.5 (9.7–24.3) 13.4 (6.6–22.2) .638
r’s disease; F, female; M, male; MMSE, mini-mental state examination; NA,
1–40; Ab1–42, amyloid b1–42; AU, arbitrary units; ELISA, enzyme-linked
rogranin and three commercially available assays (total-tau ELISA for CSF
for CSF-Ab1–40; EUROIMMUN, Germany). Plasma samples were studied
u ELISA on the other hand. The groups were not age or gender matched. All
tatistical analyses, see “Methods.”
high tau, xP, .01 versus CTRL, {P, .05 versus AD, and #P, .05 versus
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mographic and clinical data of the population.
CSF neurogranin levels differed noticeably between the
diagnostic groups (Table 1 and Fig. 2A). Compared with the
CTRL group, CSF neurogranin concentrations were signifi-
cantly increased in MCI (P , .001; Cohen’s d 5 1.06), AD
(P, .001), and in subjects having high tau levels (P, .001).
The relationship between CSF neurogranin and CSF total-
tau, CSF Ab1–42, and CSF Ab1–40, of which group levels are
shown in Fig. 2, was also addressed. When calculating the
Spearman correlation coefficients, the MCI, AD, and high
tau groups were pooled because of the low number of partic-
ipants (n) in each individual diagnostic group. Table 2 sum-
marizes the correlation between the analytes in the CTRL
group versus this pooled AD group. CSF neurogranin and
CSF total-tau were strongly correlated in both controls
(r 5 0.713; P , .001) and AD patients (r 5 0.624;
P , .001). Between CSF neurogranin and CSF Ab1–42
(r 5 0.498; P , .01) and Ab1–40 (r 5 0.645; P , .001),
we observed positive correlations in the CTRL group,
although no link was noted with the CSF Ab1–42/CSF
Ab1–40 ratio. Then again, in AD, CSF neurogranin correlated
with this ratio CSF Ab1–42/CSF Ab1–40 (r 5 20.412;
P , .01), whereas the association with CSF Ab1–42 was ab-Fig. 2. Scatter dot plots of the analytes quantified in CSF. Summary of the concen
CSF in the different diagnostic groups: mild cognitive impairment due to Alzhei
(n 5 20), and MCI or AD with high tau-levels (High tau) (n 5 19) versus cognit
plot are the median levels. The bars represent the interquartile range. Statistical
***P , .001. Abbreviations: CSF, cerebrospinal fluid; CTRL, controls.sent. The relationship between CSF neurogranin and CSF
Ab1–40 remained in the AD groups (r 5 0.406; P , .01).
Similar observations were made for CSF total-tau: in the
CTRL group, it correlated with CSF Ab1–42 (r 5 0.663;
P , .001) as well as Ab1–40 (r 5 0.784; P , .001) but also
with CSF Ab1–42/CSF Ab1–40, albeit weakly (r 5 0.384;
P , .05). In AD, there was no association between CSF
total-tau and CSF Ab1–42, whereas a correlation remained
with CSF Ab1–40 (r 5 0.472; P , .001) and CSF Ab1–42/
CSF Ab1–40 (r 5 20.419; P , .01).
Finally, although CSF neurogranin and age correlated
in the CTRL group (Supplementary Table 2), including
age, and gender, as covariate in the regression analysis
excluded possible confounding effects of age, and gender,
on the differences in CSF neurogranin between groups
(Supplementary Fig. 3). Besides age, no correlations were
observed between CSF neurogranin and clinical parameters,
such as MMSE scores (at the time of LP) nor the change in
MMSE per year or disease duration (Supplementary Table 2,
Supplementary Fig. 4). Also, no correlations could be
detected between CSF neurogranin and apolipoprotein E
(APOE) ε4 alleles or the albumin CSF/serum ratio. A
weak nonsignificant correlation was noted with HCV
(r 5 20.302) in case of the AD groups. One correlationtrations of neurogranin (A), total-tau (B), and the ratio Ab1–42/Ab1–40 (C) in
mer’s disease (MCI) (n 5 20); dementia due to Alzheimer’s Disease (AD)
ively healthy participants (n 5 29) (CTRL). Presented as a line in each dot
significant differences between the groups are presented on the graphs by
Table 2
Correlation matrix of CSF biomarkers in the control group (lower left) versus AD patients (upper right)
CSF biomarkers
AD patients
Neurogranin Total-tau Ab1–42 Ab1–40 Ab1–42/Ab1–40
CTRL
Neurogranin 0.624*** (n 5 59) 0.056 (n 5 59) 0.406** (n 5 59) 20.412** (n 5 59)
Total-tau 0.713*** (n 5 29) 0.110 (n 5 59) 0.472*** (n 5 59) 20.419** (n 5 59)
Ab1–42 0.498** (n 5 29) 0.663*** (n 5 29) 0.688*** (n 5 59) 0.489*** (n 5 59)
Ab1–40 0.645*** (n 5 29) 0.784*** (n 5 29) 0.907*** (n 5 29) 20.242 (n 5 59)
Ab1–42/Ab1–40 0.250 (n 5 29) 0.384* (n 5 29) 0.775*** (n 5 29) 0.505** (n 5 29)
Abbreviations: CSF, cerebrospinal fluid; AD, Alzheimer’s disease; Ab1–40, amyloid b1–40; Ab1–42, amyloid b1–42; CTRL, controls; MCI, mild cognitive
impairment; AD patients 5 groups of MCI, AD and MCI or AD with high CSF tau levels pooled.
NOTE. To determine the Spearman’s correlation coefficients, represented by the rho-values in the table, the groups of MCI, AD, and MCI or AD with high
CSF tau levels were pooled because of the low n in each group separately in this explorative study. The resulting pooled group is referred to as “AD patients” in
the top of the table. For details on statistical analyses, see “Methods.”
NOTE. *P , .05; **P , .01; and ***P , .001.
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P , .05).3.3. Relationship neurogranin and tau in paired plasma/
CSF samples
Paired plasma samples of the patients involved in the
CSF study were also examined, revealing levels of plasma
neurogranin in the ng/mL range (0.04–2.33 ng/mL; 25th–
75th percentiles). Using an in-house assembled research
ELISA, we were able to measure tau in 98% of these
plasma samples as well. As summarized in Table 1, thereFig. 3. Correlation analysis of neurogranin and tau in plasma and CSF. Summary of
total-tau (B), as well as of the relationship between neurogranin and total-tau level
paired CSF/plasma study are depicted: mild cognitive impairment due to Alzhei
(n5 20), and MCI or AD with high tau-levels (high tau) (n5 19) versus cognitive
analysis, no significant correlations were found, except for (D). Abbreviations: Cwere no statistically significant differences in plasma neu-
rogranin between the diagnostic groups nor did the plasma
levels correlate with the amounts in CSF (Fig. 3A). Simi-
larly, there were no substantial differences in tau levels be-
tween the groups neither did the levels of tau correlate
in CSF and plasma (Fig. 3B). Also, unlike in CSF
(Fig. 3D), neurogranin and tau did not correlate in plasma
(Fig. 3C). Remarkably, CSF total-tau did significantly,
although weakly, correlate with plasma neurogranin (r 5
20.272, P , .05).
Finally, there was no correlation between plasma neuro-
granin (or tau) and MMSE at LP, MMSE change per yearthe relationship between levels in CSF and plasma of neurogranin (A) and of
s in plasma (C) and CSF (D). The different diagnostic groups included in the
mer’s disease (MCI) (n 5 20); dementia due to Alzheimer’s disease (AD)
ly healthy participants (n5 29) (CTRL). Based on Spearman’s r correlation
SF, cerebrospinal fluid; CTRL, controls.
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HCV rating (Supplementary Table 3).4. Discussion
The need for thoroughly characterized molecular assays
has been recently demonstrated for the classical AD
biomarker CSF tau. Apparently, CSF tau occurs predomi-
nantly as a series of N-terminal and mid-domain fragments.
Consequently, immunoassays targeting specifically N-ter-
minal and mid-domain tau fragments are diagnostically
valuable [15]. Regarding neurogranin, using mass spectrom-
etry, the protein is detected in CSF as several C-terminal
fragments, whereas only minor quantities of full-length neu-
rogranin are present [12]. Therefore, we designed an ELISA
based on the mAb Ng7 and a commercial pAb, both
targeting neurogranin C-terminally, in the collagen-like
domain of the protein. Notably, cross-reactivity of both
Abs toward some abundant types of collagen, i.e. type I,
III, and IV, was excluded. However, the assay still needs
further refinement. Optimally, additional, well-defined
monoclonal antibodies are developed that can supplemen-
tary add specificity to the assay. Mass spectrometry identi-
fied 15 different C-terminal peptides of neurogranin in
CSF [12]. Some of these peptides end at the last amino
acid of neurogranin, i.e. aa78, but others end at aa76, 75,
or 65. The pAb used in this study specifically targets
an intact C-terminus, so it would not detect truncated
C-terminal fragments ending at aa76 or less. Apart from
C-terminal truncation, there are other posttranslational
modifications of neurogranin as well [26–28], such as
phosphorylation at S36, recognized to be associated with
memory. Finally, although the current ELISA enables
analysis of neurogranin in all patients, the analytical
sensitivity needs to be increased, allowing quantification
in all samples, particularly control samples where
neurogranin concentrations are low.
Although neurogranin is predominantly found in brain
cortical regions [29], plasma proteomics efforts unequivocally
demonstrate neurogranin in the blood, even in the ng/mL
concentrations [13]. Reported possible sources are based on
transcriptional data, blood platelets [30], and lymphocytes
[31], or, as e.g. demonstrated by immunohistochemistry, endo-
thelial cells [32,33]. Our study indeed confirmed levels of
neurogranin in a range of ng/mL, corroborating most recent
findings based on immunodetection [14]. However, in plasma,
no significant differences in mean neurogranin levels between
diagnostic groups were seen neither were the plasma levels
correlated with CSF levels. Using an in-house designed sensi-
tive ELISA, we made similar observations with tau.While tau
levels were lower in plasma than in CSF, mean plasma levels
between the different groups did not differ and CSF-plasma
levels were not correlated. This is in line with earlier studies
where plasma tau did not differ between control, MCI, or
AD patients [16]. Combined, it suggests that the relationship
between the levels of a particular analyte in CSF and plasmais not straightforward or that valuable CSF biomarkers
are not necessarily valuable as plasma biomarker. It is
possible that changes in plasma levels only occur in advanced
stages of AD, with extensive neurodegeneration, as already
suggested for tau [16].Especially regardingneurogranin, early,
minor pathologic changes in plasma levels are possibly unde-
tectable due to the high physiological levels. Nonetheless,
these high concentrations in the blood do not seem to affect
CSF levels of neurogranin, excluding possible confounding
effects and affirming CSF neurogranin as potential CSF AD
biomarker.
During this explorative clinical study, a highly significant
correlation between CSF neurogranin and CSF tau levels was
noted, as previously described [11,12]. Although tau is a
well-established axonal protein, recent reports located tau
also in synapses, in both normal and AD brain [34–36].
Because CSF tau and CSF neurogranin correlate strongly,
they possibly both reflect synaptic damage. However, in a
recent confirmatory longitudinal CSF study on AD, no
change in CSF tau was detected in contrast to three of
four longitudinal dynamic biomarkers related to synaptic
integrity, e.g. chromogranin, and which were also highly
correlated with CSF tau [37]. This suggests that synaptic de-
sintegrity, reflected by increased CSF levels of these synaptic
proteins, might occur earlier than structural degenerations
mirrored by CSF tau. Additionally, the current CSF
biomarker panel, including CSF tau, lack prognostic value
regarding onset of cognitive deterioration [1]. Although in
the present study the potential of neurogranin as CSF
biomarker to discriminate AD from cognitively normal has
been confirmed, the prognostic value now needs to be fully
validated. Specifically, although a link was observed between
neurogranin and cognitive decline in a previous study [12],
no correlations with cognitive markers, such as (change in)
MMSE and semiquantitative measurements of brain atrophy,
reached statistical significance in the present study. On the
other hand, this might be due to the exploratory, retrospective
nature of the study, involving relatively small patient groups
and a not yet fully developed ELISA. To resolve this issue,
larger clinical studies will be designed to validate the prog-
nostic value of neurogranin. These verification studies will
involve a refined ELISA and include well-defined patients
groups as well as age-matched controls, all with clinical
and neuropsychological follow-up.
During the study, a correlation between CSF neurogranin,
and also tau as expected [38], was noted with CSFAb1–40, in
both the control and AD groups. Remarkably, neither CSF
neurogranin nor tau correlated with CSF Ab1–42 in AD.
Further analysis, however, showed a negative correlation be-
tween CSF neurogranin and the CSFAb1–42/CSFAb1–40 ra-
tio. Because this negative correlation was also observed in
the case of CSF tau (confirmed by unpublished clinical
studies), these data link synaptic and/or axonal loss to altered
Amyloid Precursor Protein (APP) metabolism for the first
time. In cellular and animal models for AD, CSF Ab1–42/
CSF Ab1–40 has already been studied in relation to
A. De Vos et al. / Alzheimer’s & Dementia 11 (2015) 1461-14691468g-secretase dysfunction [39], which corroborates a study in
human brain tissue and CSF [40]. Furthermore, recent
studies using CSF Ab1–42/CSF Ab1–40 point toward better
diagnostic performance than CSF Ab1–42 [17,41]. Perhaps
this is related to the accuracy of measuring the Ab
analytes separately. Especially CSF Ab1–42 is affected by
many confounding factors [42]. Recent advancements in
mass spectrometry analysis of CSFAb peptides could, how-
ever, help in measuring this ratio more precisely [43,44]. In
combination with second generation immunoassays, this
would allow to further explore the link between synaptic/
axonal loss and g-secretase dysfunction.
In conclusion, using two C-terminal anti-neurogranin
antibodies, highly specific for the collagen-like domain of
the protein, we were able to quantify C-terminal neurogra-
nin in plasma and CSF, with an analytical sensitivity of
3 pg/mL, with synthetic full-length neurogranin as a cali-
brator. During this explorative study, the potential of neuro-
granin as a CSF biomarker for AD has been confirmed
which inspires us to design larger clinical, longitudinal
studies to further substantiate the probable diagnostic
and/or prognostic value of CSF neurogranin. As tools,
straightforward immunoassays can be used, as demon-
strated by the described ELISA.Acknowledgments
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1. Systematic review: Although analyzing CSF bio-
markers tau and Ab1–42 allows clinical diagnosis of
Alzheimer’s disease (AD) before dementia, it has
poor prognostic value regarding onset of cognitive
decline. Recently, CSF neurogranin, a postsynaptic
protein involved in memory consolidation, was
shown to correlate to cognitive decline in prodromal
AD. Also, CSF neurogranin circulates predomi-
nantly as C-terminal fragments.
2. Interpretation: In this study, anELISAquantifying spe-
cifically neurogranin fragments with intact C-terminus
confirmed increasedCSFneurogranin in thewhole dis-
ease spectrum of AD. While in paired CSF-plasma
samples high levels of plasma neurogranin were
confirmed, no correlation between CSF and plasma
neurogranin was found. Thus, increased CSF neuro-
granin in ADmay relate to synaptic degeneration/loss.
3. Future directions: Straightforward ELISAs, targeting
specific neurogranin fragments, can aid in harmonizing
efforts to evaluate the prognostic value of CSF neuro-
granin. Accordingly, a novel biomarker for synaptic
function in AD treatment trials could be established.References
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